{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:41:28Z","timestamp":1790649688575,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hereditary hemorrhagic telangiectasia is a rare vascular genetic disease. Epistaxis is the most frequent and disabling manifestation, and timolol appears to be a new therapeutic option as non-selective beta-blockers have <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> anti-angiogenic properties. Our main objective was to evaluate the efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. This study is a single-center, randomized, phase 2, double-blind placebo-controlled study with an allocation ratio of 1:1. It was proposed to patients with hereditary hemorrhagic telangiectasia monitored at the French Reference Center, and we included patients aged over 18 years, diagnosed with hereditary hemorrhagic telangiectasia and epistaxis. The treatment was self-administered by the patient with a posology of one spray (50\u2009\u00b5L) of timolol 0.5% or placebo in each nostril twice a day for 28 consecutive days. The primary efficacy endpoint was mean monthly epistaxis duration, assessed by monitoring epistaxis grids. A total of 58 patients were randomized and treated. The baseline characteristics were similar in the 2 groups. Mean monthly epistaxis duration measured at 3 months was not significantly different in the 26 patients receiving the drug in comparison with the placebo group (p\u2009=\u20090.54). Toxicity was low and no severe adverse events were reported. One limitation is that we included all HHT patients with nosebleeds and did not take into account history of nasal surgery or nasal crusts. Timolol, administered by nasal spray at a dose of 0.25\u2009mg in each nostril twice a day for 28 consecutive days, did not improve epistaxis in patients with hereditary hemorrhagic telangiectasia at 4 months after the beginning of the treatment.<\/jats:p>","DOI":"10.1038\/s41598-019-48502-9","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T10:03:05Z","timestamp":1566208985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial"],"prefix":"10.1038","volume":"9","author":[{"given":"Sophie","family":"Dupuis-Girod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Pitiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Bergerot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Emmanuelle","family":"Fargeton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolaine","family":"Beaudoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Decullier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Br\u00e9ant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Colombet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Philouze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Faure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Letievant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"key":"48502_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","volume":"91","author":"CL Shovlin","year":"2000","unstructured":"Shovlin, C. L. et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91, 66\u201367 (2000).","journal-title":"Am J Med Genet"},{"key":"48502_CR2","first-page":"176","volume":"34","author":"T Haitjema","year":"1996","unstructured":"Haitjema, T., Balder, W., Disch, F. J. & Westermann, C. J. Epistaxis in hereditary haemorrhagic telangiectasia. Rhinology 34, 176\u2013178 (1996).","journal-title":"Rhinology"},{"key":"48502_CR3","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s00405-004-0911-0","volume":"262","author":"I Karapantzos","year":"2005","unstructured":"Karapantzos, I. et al. Management of epistaxis in hereditary hemorrhagic telangiectasia by Nd:YAG laser and quality of life assessment using the HR-QoL questionnaire. Eur Arch Otorhinolaryngol 262, 830\u2013833 (2005).","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"48502_CR4","first-page":"40","volume":"43","author":"BJ Folz","year":"2005","unstructured":"Folz, B. J., Tennie, J., Lippert, B. M. & Werner, J. A. Natural history and control of epistaxis in a group of German patients with Rendu-Osler-Weber disease. Rhinology 43, 40\u201346 (2005).","journal-title":"Rhinology"},{"key":"48502_CR5","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1182\/blood-2006-07-034124","volume":"109","author":"L David","year":"2007","unstructured":"David, L., Mallet, C., Mazerbourg, S., Feige, J. J. & Bailly, S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109, 1953\u20131961 (2007).","journal-title":"Blood"},{"key":"48502_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/ng1294-345","volume":"8","author":"KA McAllister","year":"1994","unstructured":"McAllister, K. A. et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8, 345\u2013351 (1994).","journal-title":"Nat Genet"},{"key":"48502_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/ng0696-189","volume":"13","author":"DW Johnson","year":"1996","unstructured":"Johnson, D. W. et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13, 189\u2013195 (1996).","journal-title":"Nat Genet"},{"key":"48502_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fgene.2015.00035","volume":"6","author":"DS Ardelean","year":"2015","unstructured":"Ardelean, D. S. & Letarte, M. Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia. Frontiers in Genetics 6, 35, https:\/\/doi.org\/10.3389\/fgene.2015.00035 (2015).","journal-title":"Frontiers in Genetics"},{"key":"48502_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/bjd.12193","volume":"168","author":"W Xie","year":"2013","unstructured":"Xie, W. et al. Propranolol induces apoptosis of human umbilical vein endothelial cells through downregulation of CD147. Br J Dermatol 168, 739\u2013748, https:\/\/doi.org\/10.1111\/bjd.12193 (2013).","journal-title":"Br J Dermatol"},{"key":"48502_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1365-2133.2010.09848.x","volume":"163","author":"CH Storch","year":"2010","unstructured":"Storch, C. H. & Hoeger, P. H. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 163, 269\u2013274, https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09848.x (2010).","journal-title":"Br J Dermatol"},{"key":"48502_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1160\/TH11-11-0809","volume":"108","author":"V Albinana","year":"2012","unstructured":"Albinana, V., Recio-Poveda, L., Zarrabeitia, R., Bernabeu, C. & Botella, L. M. Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia. Thromb Haemost 108, 41\u201353, https:\/\/doi.org\/10.1160\/TH11-11-0809 (2012).","journal-title":"Thromb Haemost"},{"key":"48502_CR12","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1056\/NEJMc0708819","volume":"358","author":"C Leaute-Labreze","year":"2008","unstructured":"Leaute-Labreze, C. et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 358, 2649\u20132651, https:\/\/doi.org\/10.1056\/NEJMc0708819 (2008).","journal-title":"N Engl J Med"},{"key":"48502_CR13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.amjoto.2011.10.011","volume":"33","author":"SE Olitsky","year":"2012","unstructured":"Olitsky, S. E. Topical timolol for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. Am J Otolaryngol 33, 375\u2013376, https:\/\/doi.org\/10.1016\/j.amjoto.2011.10.011 (2012).","journal-title":"Am J Otolaryngol"},{"key":"48502_CR14","doi-asserted-by":"publisher","unstructured":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA: the journal of the American Medical Association 310, 2191\u20132194, https:\/\/doi.org\/10.1001\/jama.2013.281053 (2013).","DOI":"10.1001\/jama.2013.281053"},{"key":"48502_CR15","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jama.2016.11387","volume":"316","author":"S Dupuis-Girod","year":"2016","unstructured":"Dupuis-Girod, S. et al. Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial. JAMA: The journal of the American Medical Association 316, 934\u2013942, https:\/\/doi.org\/10.1001\/jama.2016.11387 (2016).","journal-title":"JAMA: The journal of the American Medical Association"},{"key":"48502_CR16","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jama.2016.11724","volume":"316","author":"KJ Whitehead","year":"2016","unstructured":"Whitehead, K. J. et al. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial. JAMA: The Journal of the American Medical Association 316, 943\u2013951, https:\/\/doi.org\/10.1001\/jama.2016.11724 (2016).","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"48502_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.anl.2015.12.001","volume":"43","author":"K Ichimura","year":"2016","unstructured":"Ichimura, K., Kikuchi, H., Imayoshi, S. & Dias, M. S. Topical application of timolol decreases the severity and frequency of epistaxis in patients who have previously undergone nasal dermoplasty for hereditary hemorrhagic telangiectasia. Auris Nasus Larynx 43, 429\u2013432, https:\/\/doi.org\/10.1016\/j.anl.2015.12.001 (2016).","journal-title":"Auris Nasus Larynx"},{"key":"48502_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40463-017-0235-x","volume":"46","author":"M Mei-Zahav","year":"2017","unstructured":"Mei-Zahav, M., Blau, H., Bruckheimer, E., Zur, E. & Goldschmidt, N. Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report. Journal of Otolaryngology - head & neck surgery\u2009=\u2009Le Journal d\u2019oto-rhino-laryngologie et de chirurgie cervico-faciale 46, 58, https:\/\/doi.org\/10.1186\/s40463-017-0235-x (2017).","journal-title":"Journal of Otolaryngology - head & neck surgery\u2009=\u2009Le Journal d\u2019oto-rhino-laryngologie et de chirurgie cervico-faciale"},{"key":"48502_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1089\/jop.2008.0028","volume":"25","author":"Y Yang","year":"2009","unstructured":"Yang, Y., Wu, K., Yuan, H. & Yu, M. Cytochrome oxidase 2D6 gene polymorphism in primary open-angle glaucoma with various effects to ophthalmic timolol. Journal of Ocular Pharmacology and Therapeutics: The Official Journal of the Association for Ocular Pharmacology and Therapeutics 25, 163\u2013171, https:\/\/doi.org\/10.1089\/jop.2008.0028 (2009).","journal-title":"Journal of Ocular Pharmacology and Therapeutics: The Official Journal of the Association for Ocular Pharmacology and Therapeutics"},{"key":"48502_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/00365510601034736","volume":"67","author":"T Nieminen","year":"2007","unstructured":"Nieminen, T. et al. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scandinavian Journal of Clinical and Laboratory Investigation 67, 237\u2013245, https:\/\/doi.org\/10.1080\/00365510601034736 (2007).","journal-title":"Scandinavian Journal of Clinical and Laboratory Investigation"},{"key":"48502_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1742-7843.2011.00694.x","volume":"108","author":"M Volotinen","year":"2011","unstructured":"Volotinen, M., Hakkola, J., Pelkonen, O., Vapaatalo, H. & Maenpaa, J. Metabolism of ophthalmic timolol: new aspects of an old drug. Basic & Clinical Pharmacology & Toxicology 108, 297\u2013303, https:\/\/doi.org\/10.1111\/j.1742-7843.2011.00694.x (2011).","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"48502_CR22","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1197\/j.aem.2005.06.027","volume":"12","author":"R Sikka","year":"2005","unstructured":"Sikka, R., Magauran, B., Ulrich, A. & Shannon, M. Bench to bedside: Pharmacogenomics, adverse drug interactions, and the cytochrome P450 system. Academic emergency medicine: official journal of the Society for. Academic Emergency Medicine 12, 1227\u20131235, https:\/\/doi.org\/10.1197\/j.aem.2005.06.027 (2005).","journal-title":"Academic Emergency Medicine"},{"key":"48502_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1023\/B:PHAR.0000026823.82950.ff","volume":"26","author":"S Turker","year":"2004","unstructured":"Turker, S., Onur, E. & Ozer, Y. Nasal route and drug delivery systems. Pharmacy World & Science: PWS 26, 137\u2013142 (2004).","journal-title":"Pharmacy World & Science: PWS"},{"issue":"feb11 1","key":"48502_CR24","doi-asserted-by":"publisher","first-page":"bcr2013203056","DOI":"10.1136\/bcr-2013-203056","volume":"2014","author":"N. Epperla","year":"2014","unstructured":"Epperla, N., Brilliant, M. H. & Vidaillet, H. Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants. BMJ Case Reports 2014, https:\/\/doi.org\/10.1136\/bcr-2013-203056 (2014).","journal-title":"Case Reports"},{"key":"48502_CR25","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jama.2012.250","volume":"307","author":"S Dupuis-Girod","year":"2012","unstructured":"Dupuis-Girod, S. et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA: The Journal of the American Medical Association 307, 948\u2013955, https:\/\/doi.org\/10.1001\/jama.2012.250 (2012).","journal-title":"JAMA: The Journal of the American Medical Association"},{"issue":"3","key":"48502_CR26","doi-asserted-by":"publisher","first-page":"793","DOI":"10.4161\/mabs.28025","volume":"6","author":"Sophie Dupuis-Girod","year":"2014","unstructured":"Dupuis-Girod, S. et al. ELLIPSE Study: A Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia. mAbs 6 (2014).","journal-title":"mAbs"},{"issue":"9","key":"48502_CR27","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1111\/jth.12654","volume":"12","author":"S. Gaillard","year":"2014","unstructured":"Gaillard, S. et al. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost, https:\/\/doi.org\/10.1111\/jth.12654 (2014).","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"48502_CR28","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/alr.21374","volume":"4","author":"CA Merlo","year":"2014","unstructured":"Merlo, C. A., Yin, L. X., Hoag, J. B., Mitchell, S. E. & Reh, D. D. The effects of epistaxis on health-related quality of life in patients with hereditary hemorrhagic telangiectasia. International Forum of Allergy & Rhinology 4, 921\u2013925, https:\/\/doi.org\/10.1002\/alr.21374 (2014).","journal-title":"International Forum of Allergy & Rhinology"},{"issue":"5","key":"48502_CR29","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.otohns.2006.12.019","volume":"136","author":"Urban W. Geisthoff","year":"2007","unstructured":"Geisthoff, U. W. et al. Health-related quality of life in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 136, 726\u2013733, discussion 734\u2013725 (2007).","journal-title":"Otolaryngology\u2013Head and Neck Surgery"},{"key":"48502_CR30","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/ajmg.a.35309","volume":"158A","author":"AO Geirdal","year":"2012","unstructured":"Geirdal, A. O., Dheyauldeen, S., Bachmann-Harildstad, G. & Heimdal, K. Quality of life in patients with hereditary hemorrhagic telangiectasia in Norway: a population based study. Am J Med Genet A 158A, 1269\u20131278, https:\/\/doi.org\/10.1002\/ajmg.a.35309 (2012).","journal-title":"Am J Med Genet A"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48502-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48502-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48502-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:37:58Z","timestamp":1671280678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48502-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,19]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["48502"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-48502-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,19]]},"assertion":[{"value":"23 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11986"}}